Tempus AI, Inc. (BCBA:TEMD)
Argentina · Delayed Price · Currency is ARS · Price in USD | Market Cap | 16.90T -2.5% |
| Revenue (ttm) | 2.12T +50.4% |
| Net Income | -376.93B |
| EPS | -2,123.99 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 5.44 |
| Previous Close | 5.42 |
| Day's Range | 5.44 - 5.44 |
| 52-Week Range | 3.49 - 6.32 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Tempus AI
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sc... [Read more]
Financial Performance
In 2025, Tempus AI's revenue was $1.27 billion, an increase of 83.41% compared to the previous year's $693.40 million. Losses were -$245.03 million, -67.12% less than in 2024.
Financial numbers in USD Financial StatementsNews
Why Moderna's Cancer Vaccine Matters to Investors
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not ...
Cantor Fitzgerald bullish on Tempus AI, initiates with an Overweight
As previously reported, Cantor Fitzgerald analyst Sarah James initiated coverage of Tempus AI (TEM) with an Overweight rating and $80 price target implying 28% upside in the firm’s Base Case…
Tempus AI initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Tempus AI (TEM) with an Overweight rating and $80 price target
Tempus AI upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Tempus AI (TEM) to Overweight from Neutral with a price target of $76, up from $56. The the pending acquisition of Personalis (PSNL) gives Tempus ownership of…
Tempus AI receives FDA clearance for Tempus ECG-PH
Tempus AI (TEM) announced it has received 510(k) clearance from the U.S. Food and Drug Administration, FDA, for Tempus ECG-PH, an AI-enabled software device that analyzes standard 12-lead electrocardi...
Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an...
Tempus AI price target raised to $80 from $70 at BTIG
BTIG analyst Mark Massaro raised the firm’s price target on Tempus AI (TEM) to $80 from $70 and keeps a Buy rating on the shares as part of a broader…
Tempus AI stock is soaring and it has Moderna to thank
Tempus AI (TEM) stock ripped higher on August 19 as third-party clinical breakthroughs triggered a technical short squeeze. As investors cheered TEM, it broke decisively above its major moving average...
‘Prepare for What’s Coming,’ Says Investor About Tempus AI Stock
Tempus AI (NASDAQ:TEM) stock is soaring about 22% on Wednesday, with Moderna’s huge melanoma win giving investors a new reason to reconsider the value of Tempus’ pending Personalis acquisition. Modern...
Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why
Tempus AI ($TEM) surged nearly 24% on Wednesday after a major Phase 3 cancer vaccine update from Merck ($MRK) and Moderna ($MRNA). The news instantly justified Tempus AI’s recent $1.5…
Tempus AI added to CellCarta’s CDx commercialization lab network
Tempus AI (TEM) announced a strategic collaboration with CellCarta, a global CRO laboratory supporting the biopharmaceutical industry. Under the agreement, CellCarta will include Tempus in its CDx Com...
CellCarta Adds Tempus to CDx Commercialization Lab Network
Tempus joins as a second commercial laboratory partnership to support oncology-focused access within CellCarta's CDx Accelerator Model. MONTREAL, Aug. 6, 2026 /PRNewswire/ -- CellCarta, a global CRO l...
Personalis says not providing guidance or conducting earnings call
As a result of the announcement on July 20, 2026 that Personalis (PSNL) and Tempus AI (TEM) have entered into an Agreement and Plan of Merger, Personalis will no longer…
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced study results demonstrating tha...
Tempus AI Earnings Call Transcript: Q2 2026
Q2 revenue grew 22% year-over-year, driven by strong Diagnostics and Data & Apps performance, with major pharma deals and FDA approvals setting up significant future revenue gains. The Personalis acquisition and new financing support continued growth and margin expansion.
Tempus AI Earnings release: Q2 2026
Tempus AI released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Tempus AI Quarterly report: Q2 2026
Tempus AI has published its Q2 2026 quarterly earnings report on July 30, 2026.
Tempus AI Slides: Q2 2026
Tempus AI has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
Tempus Reports Second Quarter 2026 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today reported financial results for the quarter ended June 30, ...
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of its OneO...
Tempus AI Buys Personalis for $1.5 Billion, and Both Stocks Sink
Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.